OncoMatch/Clinical Trials/NCT06939166
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Is NCT06939166 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies UCAR T-cell for neuromyelitis optica spectrum disorders.
Treatment: UCAR T-cell — This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: BCMA positive
Required: CD19 positive
Lab requirements
Cardiac function
Subjects with insufficient cardiac function [excluded]
Subjects with insufficient cardiac function [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify